CellCentric's Scientific Director Nessa Carey and Programme Manager Jonathan Best publish a review on epigenetics and non-oncology therapeutic indications in Drug Discovery Today.
CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has ties to over 30 leading research labs in epigenetics. The company has proven its ability to bring together privileged fragmented insights and data from multiple sources to help identify and prioritise new epigenetic targets and accelerate related drug discovery.
The company’s activities to date are focused on oncology. However there are broader potential applications of epigenetic understanding to novel drug discovery beyond cancer indications, as highlighted in this new article:
Epigenetic therapies for non-oncology indications.
Best JD, Carey N, Drug Discovery Today, Nov 2010 [Epub ahead of print]
A copy of the article can be viewed by clicking on the following link: Best&Carey DDT Nov10.pdf
For further information contact:
Nessa Carey, Scientific Director, CellCentric Tel: + 44 (0) 1799 531 130
Epigenetics concerns the processes that help govern chromatin structure and function, by which cell fate is controlled. This is an emerging field that is leading to a series of novel approaches to intractable diseases, including cancer. DNA methyltransferase and histone deacetylase inhibitors have pioneered the therapeutic potential of the space, but it is clear that there are many other targets associated with epigenetics that could have real clinical impact.
CellCentric is an innovation company focused on epigenetics. The company’s business model, based on a global network of tied leading researchers, gives CellCentric the greatest chance of success in delivering the next wave of epigenetic opportunities. The company identifies novel targets that it prioritises and takes into early drug discovery, as well as novel tools for analysing epigenetic candidates.
Currently CellCentric is running small molecule discovery programmes on multiple novel targets that have been prioritised from a wide pool of candidates identified through disclosures from Principal Investigators in its network. Targets include histone methyltransferases and demethylases, and epigenetic enzymes that act via ubiquitin. Each programme benefits from on-going input from the leading researchers in the field.
CellCentric was founded in 2004 with Prof Azim Surani of the University of Cambridge.